Publications by authors named "Yuma Nonomiya"
Article Synopsis
- Trastuzumab deruxtecan (T-DXd) has shown effectiveness and manageable side effects in patients with advanced gastric and breast cancer, and it's recently approved in Japan.
- A study reviewed the medical records of 36 patients (19 with gastric cancer and 17 with breast cancer) who received T-DXd, focusing on adverse events during the first three treatment cycles.
- Gastrointestinal issues were the most common side effects, with nausea being particularly more prevalent in females, highlighting the importance of managing these toxicities in clinical practice.
Poly (ADP-ribose) polymerases (PARPs) are involved in various cellular events, including DNA repair. PARP inhibitors including olaparib and rucaparib, have been specially developed against breast and ovarian cancers deficient in DNA repair systems. In this study, we found that PARP1-defective olaparib-resistant A2780 cells (ola-R cells) cells were still sensitive to two PARP inhibitors, rucaparib and veliparib.
View Article and Find Full Text PDFRegorafenib is a multikinase inhibitor for the treatment of metastatic colorectal cancer. Regorafenib-induced hand-foot skin reaction (HFSR) is a common side effect during treatment. The reported frequency of HFSR was 80% (grade 3: 28%) in the Japanese subpopulation in the CORRECT trial; however, more detailed data regarding HFSR in terms of onset and sites of susceptibility are unclear.
View Article and Find Full Text PDFArticle Synopsis
- * Researchers found that AKT3, a member of the AKT family responsible for cell growth and drug resistance, is overexpressed in cells resistant to AURK inhibitors, creating challenges for effective cancer treatment.
- * The study demonstrates that combining an AKT inhibitor (AZD5363) with AURK inhibitor (VX-680) can enhance cancer cell sensitivity, as depleting AKT3 makes cells more susceptible to the AURK inhibitor while also reducing
Polo-like kinase (PLK) is a cell-cycle regulator that is overexpressed in several cancer cell types. Polo-like kinase is considered a novel target for cancer therapies, and several PLK inhibitors (PLKis), including BI 2536, BI 6727, and GSK461364, have been developed. In this study, we established five BI 2536-resistant cell lines from human colorectal cancer HCT 116 cells, to explore the resistance mechanism and identify predictable biomarkers of PLKis.
View Article and Find Full Text PDF